secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0001193125-24-281696
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis secures $50M Merck investment, extends Moderna pact, expands Tempus deal
--------------------------------------------------------------------------------

- Merck to purchase 14,044,943 shares at $3.56/share for ~$50M; closing expected Dec 19, 2024.
- Merck receives standstill, information, pro-rata participation, and voting rights until 2 years post-close.
- Tempus AI authorized to sell NeXT Personal minimal residual disease test to pharma/biotech clients.
- Moderna extends SOW for V940/mRNA-4157 INT program to up to 10 years; Moderna can license IP for low double-digit millions.
- Personalis to use $10M of proceeds to open ISO-certified lab outside US, mutually agreed with Merck.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312524281696/0001193125-24-281696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312524281696/d149682d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-281696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer